FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387207987> ?p ?o ?g. }

• W4387207987 endingPage "e328" @default.
• W4387207987 startingPage "e328" @default.
• W4387207987 abstract "A modestly hypofractionated course of chemoradiation (CRT) consisting of 36 Gy/15 fractions (F) concurrent with gemcitabine used in PREOPANC and phase II trials has become increasingly common for the treatment of borderline resectable (BR) and locally advanced (LA) pancreatic cancer (PC). Achieving an R0 resection remains a key prognostic factor in PC. We tested whether escalating dose beyond standard dosing (SD) of 36-39 Gy/15 F (or 50-54 Gy/25-30 F) would improve R0 resection rates and outcomes while respecting nearby organs at risk.This was a retrospective analysis of consecutive patients at our institution from 2012-2022 with BR/LA PC treated with moderate dose escalated (MDE) (45 Gy/15 F, N = 45) or SD (36-39 Gy/15 F, N = 68 or 50-54 Gy/25-30 F, N = 25) CRT. For MDE, a 5 mm expansion from the duodenum, small bowel, and stomach was created (GI_PRV); PTV was cropped from this structure and prescribed 45 Gy/15 F. The primary endpoint was R0 resection rate with secondary endpoints of cumulative incidence of local progression (LP, recurrence after surgery/imaging progression if no surgery) with death as a competing risk (LP after occurrence of distant metastasis [DM] were still captured), cumulative incidence of DM, and overall survival (OS). Univariable and multivariable competing risks regression analyses were performed to determine the association between baseline covariates and LP.We identified 45 patients treated with MDE and 93 treated with SD. Most patients presented with BR disease (55.6% MDE; 54.8% SD) and received neoadjuvant chemotherapy with FOLFIRINOX (98% MDE; 99% SD). All patients in the MDE group and 99% in the SD group received concurrent chemotherapy with gemcitabine used most often (96% MDE; 77% SD). Median follow-up was 17 m (IQR 13-27 m). Surgical resection rates were similar between groups (33.3% MDE vs. 39.8% SD, p = 0.46). Amongst patients that had surgery, R0 resection rates were non-significantly higher in the MDE group (73.3% vs. 47.4%, p = 0.09). Cumulative incidence of LP at 18 m was significantly lower in the MDE group (9.0% vs. 24.8%, p = 0.04). No difference in rates of DM (51.2% MDE vs. 59.6% SD, p = 0.92) or OS at 18 m (53.9% vs. 53.6%, p = 0.89) were observed. On multivariable analysis, MDE (HR = 0.39, p = 0.03) and pancreatic head location (HR = 0.51, p = 0.04) were the only factors independently associated with LP. Rates of grade 2+ gastrointestinal toxicity during CRT (20% MDE vs. 20.9% SD, p = 0.91) and ≤90 days of completing CRT (11.6% MDE vs. 14.8%, p = 0.62) were similar between groups, as were rates of grade 3+ hematologic toxicity (52.3% MDE vs. 41.3% SD, p = 0.23).In this single institutional study, we found MDE is a simple, safe, and effective strategy associated with improved local control, higher R0 resection rates, and similar toxicity to SD CRT for patients with BR/LA PC. Further prospective data is needed to clarify the role of dose-escalated RT in the management of this lethal malignancy." @default.
• W4387207987 created "2023-09-30" @default.
• W4387207987 creator A5003582204 @default.
• W4387207987 creator A5026796794 @default.
• W4387207987 creator A5027884875 @default.
• W4387207987 creator A5030652856 @default.
• W4387207987 creator A5040079785 @default.
• W4387207987 creator A5040916194 @default.
• W4387207987 creator A5043067705 @default.
• W4387207987 creator A5068961161 @default.
• W4387207987 creator A5070002272 @default.
• W4387207987 creator A5081164792 @default.
• W4387207987 date "2023-10-01" @default.
• W4387207987 modified "2023-10-17" @default.
• W4387207987 title "Outcomes of Moderately Dose Escalated Hypofractionated Chemoradiation for Pancreatic Cancer" @default.
• W4387207987 doi "https://doi.org/10.1016/j.ijrobp.2023.06.2376" @default.
• W4387207987 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37785161" @default.
• W4387207987 hasPublicationYear "2023" @default.
• W4387207987 type Work @default.
• W4387207987 citedByCount "0" @default.
• W4387207987 crossrefType "journal-article" @default.
• W4387207987 hasAuthorship W4387207987A5003582204 @default.
• W4387207987 hasAuthorship W4387207987A5026796794 @default.
• W4387207987 hasAuthorship W4387207987A5027884875 @default.
• W4387207987 hasAuthorship W4387207987A5030652856 @default.
• W4387207987 hasAuthorship W4387207987A5040079785 @default.
• W4387207987 hasAuthorship W4387207987A5040916194 @default.
• W4387207987 hasAuthorship W4387207987A5043067705 @default.
• W4387207987 hasAuthorship W4387207987A5068961161 @default.
• W4387207987 hasAuthorship W4387207987A5070002272 @default.
• W4387207987 hasAuthorship W4387207987A5081164792 @default.
• W4387207987 hasConcept C120665830 @default.
• W4387207987 hasConcept C121332964 @default.
• W4387207987 hasConcept C121608353 @default.
• W4387207987 hasConcept C126322002 @default.
• W4387207987 hasConcept C143998085 @default.
• W4387207987 hasConcept C167135981 @default.
• W4387207987 hasConcept C203092338 @default.
• W4387207987 hasConcept C2780210213 @default.
• W4387207987 hasConcept C2780258809 @default.
• W4387207987 hasConcept C2989005 @default.
• W4387207987 hasConcept C535046627 @default.
• W4387207987 hasConcept C61511704 @default.
• W4387207987 hasConcept C71924100 @default.
• W4387207987 hasConcept C72563966 @default.
• W4387207987 hasConcept C88879693 @default.
• W4387207987 hasConceptScore W4387207987C120665830 @default.
• W4387207987 hasConceptScore W4387207987C121332964 @default.
• W4387207987 hasConceptScore W4387207987C121608353 @default.
• W4387207987 hasConceptScore W4387207987C126322002 @default.
• W4387207987 hasConceptScore W4387207987C143998085 @default.
• W4387207987 hasConceptScore W4387207987C167135981 @default.
• W4387207987 hasConceptScore W4387207987C203092338 @default.
• W4387207987 hasConceptScore W4387207987C2780210213 @default.
• W4387207987 hasConceptScore W4387207987C2780258809 @default.
• W4387207987 hasConceptScore W4387207987C2989005 @default.
• W4387207987 hasConceptScore W4387207987C535046627 @default.
• W4387207987 hasConceptScore W4387207987C61511704 @default.
• W4387207987 hasConceptScore W4387207987C71924100 @default.
• W4387207987 hasConceptScore W4387207987C72563966 @default.
• W4387207987 hasConceptScore W4387207987C88879693 @default.
• W4387207987 hasIssue "2" @default.
• W4387207987 hasLocation W43872079871 @default.
• W4387207987 hasLocation W43872079872 @default.
• W4387207987 hasOpenAccess W4387207987 @default.
• W4387207987 hasPrimaryLocation W43872079871 @default.
• W4387207987 hasRelatedWork W114644245 @default.
• W4387207987 hasRelatedWork W1964744725 @default.
• W4387207987 hasRelatedWork W1969578744 @default.
• W4387207987 hasRelatedWork W2005537476 @default.
• W4387207987 hasRelatedWork W2319496893 @default.
• W4387207987 hasRelatedWork W2376347278 @default.
• W4387207987 hasRelatedWork W2744534349 @default.
• W4387207987 hasRelatedWork W2900510703 @default.
• W4387207987 hasRelatedWork W2973816194 @default.
• W4387207987 hasRelatedWork W2187801383 @default.
• W4387207987 hasVolume "117" @default.
• W4387207987 isParatext "false" @default.
• W4387207987 isRetracted "false" @default.
• W4387207987 workType "article" @default.